Poland· PL-100127750

Sulperazon 1 g

A cefoperazon und beta-lactamase-inhibitor product containing cefoperazonum + sulbactamum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 2 of our 19 countries.

ATC J01DD62

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSulperazon 1 gATCJ01DD62REGISTER NO.PL-100127750PACKS LISTED1CHECKEDSeptember 6, 2026

Where it is registered

Cefoperazon und beta-lactamase-inhibitor is registered in 2 of 19 countries.

Countries holding a registration under ATC J01DD62 (cefoperazon und beta-lactamase-inhibitor), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose

Cefoperazon und beta-lactamase-inhibitor · ATC J01DD62

2 / 19 countries

  • Czechiaprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Cefoperazonum + Sulbactamum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
J01DD62
ATC class
Cefoperazon und Beta-Lactamase-Inhibitor
Defined daily dose
4 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 6, 2026

Packs & prices · 1

  • gtin
    05909991083311

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Cefoperazon und beta-lactamase-inhibitor in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cefoperazon und beta-lactamase-inhibitor products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Bulgaria · Сулцеф, Цефопефаст-С
  • Cyprus · Sulbazon, Sulcef
  • Romania · Sulcef
  • Slovakia · Sulcef

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f8275fb9-6d0c-4712-b229-3dd4eabacbcb
GET /v1/drugs/f8275fb9-6d0c-4712-b229-3dd4eabacbcb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań i infuzji",
  "source": "urpl",
  "strength": "500 mg + 500 mg",
  "packaging": "05909991083311 ¦ Lz ¦ 58460\n1 fiol.  proszku",
  "substance": "Cefoperazonum natricum 500 mg + Sulbactamum natricum 500 mg",
  "common_name": "Cefoperazonum + Sulbactamum",
  "pl_product_id": "100127750",
  "pozwolenie_nr": "10833",
  "auth_procedure": "NAR",
  "authorisation_validity": "2023-09-08"
}

See everything about cefoperazon und beta-lactamase-inhibitor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.